No approved OA therapies reduce pain and slow joint damage. Mouse data suggested that inhibiting IL-1α and -1β with ABT-981 would reduce pain and slow structural progression in EHOA. Objectives: To test the efficacy and safety of ABT-981 in EHOA. Methods: Subjects with HOA per ACR criteria, ≥3 inflamed IP joints (tender, swollen, or both), hand pain ≥6 (scale 0-10), and ≥1 erosive IP joint on X-ray (Verbruggen-Veys) were randomized to placebo (PBO) or ABT-981 200 mg SC every 2 wk for 26 wk. The primary outcome was AUSCAN hand pain at 16 wk. Subjects had radiographs of both hands and MRI of the index hand at baseline and 26 wk. Both radiographs (Verbruggen-Veys, GUSS™, OARSI, Kellgren-Lawrence [KL]) and MRIs (HOAMRIS) were read by 2 independent central readers. A modified intent-to-treat population (ie, randomized and treated) was analyzed. Continuous efficacy endpoints were assessed using ANCOVA models with treatment and country as main factors and baseline measurements as covariates with LOCF imputation for the primary endpoint. Results: Of 131 treated subjects (85% women; mean age 66 y), 61/67 randomized to PBO and 49/64 to ABT-981 completed the study; subject characteristics were well matched. AUSCAN pain was not significantly different vs PBO at wk 16 (P=0.39; Table 1, Figure) ; X-ray data and other endpoints also were not statistically different vs PBO (Table 1) . ABT-981 significantly decreased hsCRP, neutrophils, IL-1α, and IL-1β. Immunogenicity had no impact on ABT-981 pharmacokinetics. Besides injection site reactions and neutropenia, ABT-981 was well tolerated and safety was similar vs PBO, with no serious infections ( Table 2) .
Objectives: To describe the prevalence of early osteophytes (OPs) that were detected by magnetic resonance imaging (MRI) but not by X-ray in older adults and to evaluate the longitudinal associations with knee pain and structural changes. Methods: 837 participants (mean age 62 years, 50% female) were randomly selected from local community at baseline. T1-or T2-weighted fat suppressed MRI was used to assess knee OPs, cartilage volume, cartilage defects and bone marrow lesions (BMLs) at baseline and after 2.6 years. Knee pain was assessed by self-administered Western Ontario and McMaster Osteoarthritis (WOMAC) Index questionnaire at baseline and after 5 years. X-ray-detected OPs were assessed at baseline using the Osteoarthritis Research Society International atlas. OPs detected only by MRI but not by standard X-ray were defined as early OPs. OPs detected by both MRI and X-ray were defined as definite OPs.
Results:
The prevalence of early OPs was 75% while the prevalence of definite OPs was 10% in total knee at baseline. Compared with participants without any OPs, participants with early OPs and with definite OPs had greater cartilage volume loss and increased cartilage defects and BMLs over 2.6 years. Presence of early medial tibiofemoral OPs predicted decreases in total knee pain over 5 years, while definite OPs predicted increases in total knee pain, after adjustment for relevant covariates. 
